NCT02065063 - A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2014

Primary Completion Date

June 23, 2016

Study Completion Date

June 23, 2016

Conditions

Cancer

Interventions

DRUG

Trametinib

Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.

DRUG

Palbociclib

Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.

Trial Locations (3)

GSK Investigational Site, Nashville

GSK Investigational Site, Boston

GSK Investigational Site, Houston